

David Webb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7542302/publications.pdf>

Version: 2024-02-01

135
papers

11,612
citations

44069

48
h-index

28297

105
g-index

139
all docs

139
docs citations

139
times ranked

12521
citing authors

#	ARTICLE	IF	CITATIONS
1	Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. <i>Circulation</i> , 2022, 145, 416-423.	1.6	35
2	Budget impact analysis of a pilot polypharmacy clinic. <i>British Journal of Health Care Management</i> , 2022, 28, 1-9.	0.2	0
3	Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD). <i>American Journal of Hypertension</i> , 2021, 34, 92-99.	2.0	7
4	Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. <i>IScience</i> , 2021, 24, 101937.	4.1	16
5	Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 969-989.	2.5	9
6	Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 991-1028.	2.5	20
7	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 456-465.	2.0	19
8	Urotensin receptor in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	0
9	Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 375-377.	0.7	1
10	The acute pressure natriuresis response is suppressed by selective ETA receptor blockade. <i>Clinical Science</i> , 2021, , .	4.3	2
11	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020, 177, 5467-5488.	5.4	65
12	Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury. <i>Kidney International</i> , 2020, 98, 1193-1209.	5.2	8
13	Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. <i>Cell Stem Cell</i> , 2020, 27, 822-839.e8.	11.1	51
14	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQqO 0 0 TgBT /Overlock 10	8.6	13
15	The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. <i>Kidney International</i> , 2020, 98, 323-342.	5.2	72
16	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020, 41, 1606-1607.	2.2	18
17	Improving medication safety: focus on prescribers and systems. <i>Lancet, The</i> , 2019, 394, 283-285.	13.7	14
18	Renal denervation therapy for hypertension: still on trial. <i>Heart</i> , 2019, 105, 1452-1453.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Pharmacoevidence: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1907-1924.	2.4	15
20	Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. <i>EClinicalMedicine</i> , 2019, 11, 11-17.	7.1	44
21	Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase) Tj ETQq1 1 0.784314 rgBT /Over 16	2.7	16
22	Retinal fingerprints for precision profiling of cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2019, 16, 379-381.	13.7	12
23	Endothelins in cardiovascular biology and therapeutics. <i>Nature Reviews Cardiology</i> , 2019, 16, 491-502.	13.7	154
24	011.â€fCHORIORETINAL THICKNESS TRACKS DISEASE ACTIVITY IN CLINICAL ANCA VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
25	A novel role for myeloid endothelin-B receptors in hypertension. <i>European Heart Journal</i> , 2019, 40, 768-784.	2.2	31
26	Endothelin signalling mediates experience-dependent myelination in the CNS. <i>ELife</i> , 2019, 8, .	6.0	64
27	Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
28	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 464-475.	11.4	206
29	Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease. <i>Kidney International</i> , 2018, 93, 270.	5.2	3
30	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. <i>Journal of Hypertension</i> , 2018, 36, 451-461.	0.5	19
31	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. <i>Journal of Hypertension</i> , 2018, 36, 462-471.	0.5	13
32	Long-term adverse effects of paracetamol â€“ a review. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2218-2230.	2.4	145
33	First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis. <i>Hypertension</i> , 2017, 70, 192-200.	2.7	7
34	Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7343 UK final-year medical students. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2249-2258.	2.4	50
35	Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes. <i>Diabetologia</i> , 2017, 60, 1400-1408.	6.3	14
36	Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. <i>Hypertension</i> , 2017, 69, 275-285.	2.7	12

#	ARTICLE	IF	CITATIONS
37	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.	2.2	6
38	Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model. <i>Toxicological Sciences</i> , 2017, 159, 380-391.	3.1	19
39	A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2339-2342.	2.4	3
40	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	74
41	Arterial stiffness & Sri Lankan chronic kidney disease of unknown origin. <i>Scientific Reports</i> , 2016, 6, 32599.	3.3	6
42	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , 2016, 6, e010313.	1.9	58
43	Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. <i>Kidney International</i> , 2016, 89, 1125-1135.	5.2	62
44	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 34.	3.5	25
45	Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals. <i>Clinical Toxicology</i> , 2016, 54, 53-55.	1.9	31
46	Endothelin. <i>Pharmacological Reviews</i> , 2016, 68, 357-418.	16.0	574
47	Therapeutic potential of endothelin receptor antagonism in kidney disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R388-R397.	1.8	18
48	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 136-147.	11.4	99
49	Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. <i>JCI Insight</i> , 2016, 1, e89173.	5.0	70
50	Generation and 3-Dimensional Quantitation of Arterial Lesions in Mice Using Optical Projection Tomography. <i>Journal of Visualized Experiments</i> , 2015, , e50627.	0.3	3
51	Targeting Blood Vessel Stiffness to Protect Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2107-2109.	4.5	2
52	Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism. <i>Journal of the American Heart Association</i> , 2015, 4, e001624.	3.7	16
53	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. <i>BMJ Open</i> , 2015, 5, e008086.	1.9	7
54	Prescribing safety: ensuring that new graduates are prepared. <i>Lancet, The</i> , 2015, 385, 579-581.	13.7	39

#	ARTICLE	IF	CITATIONS
55	Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. <i>Journal of Lipid Research</i> , 2015, 56, 413-422.	4.2	70
56	Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations. <i>Archives of Disease in Childhood</i> , 2015, 100, 662-666.	1.9	28
57	Endothelin in Nondiabetic Chronic Kidney Disease: Preclinical and Clinical Studies. <i>Seminars in Nephrology</i> , 2015, 35, 176-187.	1.6	13
58	Imaging of cardiovascular risk in patients with Turner's syndrome. <i>Clinical Radiology</i> , 2015, 70, 803-814.	1.1	28
59	Sildenafil improves renal function in patients with pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 235-241.	2.4	22
60	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. <i>BMJ Open</i> , 2015, 5, e008951.	1.9	13
61	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet</i> , The, 2015, 386, 2059-2068.	13.7	904
62	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: Figure A1. <i>BMJ Open</i> , 2015, 5, e007645.	1.9	10
63	Direct Action of Endothelin-1 on Podocytes Promotes Diabetic Glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1050-1062.	6.1	87
64	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 636-646.	2.8	1,446
65	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 521-527.	0.6	33
66	Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. <i>Lancet</i> , The, 2014, 383, 697-704.	13.7	172
67	Prevalence and Causes of Prescribing Errors: The PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) Study. <i>PLoS ONE</i> , 2014, 9, e79802.	2.5	147
68	A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1396-1405.	2.4	36
69	Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 31-36.	6.1	33
70	Value-based medicine pricing: NICE work?. <i>Lancet</i> , The, 2011, 377, 1552-1553.	13.7	16
71	Circulating microRNAs as potential markers of human drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 1767-1776.	7.3	464
72	11 β -Hydroxysteroid Dehydrogenase Type 2 Deficiency Accelerates Atherogenesis and Causes Proinflammatory Changes in the Endothelium in Apoe ^{-/-} Mice. <i>Endocrinology</i> , 2011, 152, 236-246.	2.8	89

#	ARTICLE	IF	CITATIONS
73	Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease. <i>Hypertension</i> , 2011, 57, 772-779.	2.7	138
74	DORADO: Opportunity Postponed. <i>Hypertension</i> , 2010, 56, 806-807.	2.7	21
75	Greater Functional ET _B Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy Men. <i>Hypertension</i> , 2010, 55, 1406-1411.	2.7	14
76	Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease. <i>Hypertension</i> , 2009, 54, 113-119.	2.7	113
77	Reply to J Rood and SR Smith. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 249-250.	4.7	3
78	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3228-3234.	0.7	47
79	Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. <i>Heart</i> , 2007, 93, 2-4.	2.9	37
80	The Endothelin System and Its Antagonism in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 943-955.	6.1	216
81	Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. <i>British Journal of Cancer</i> , 2005, 92, 2148-2152.	6.4	82
82	A Comparison of the Haemodynamic Effects Pentaerythritol Tetranitrate and Isosorbide Mononitrate in Healthy Men. <i>Clinical Science</i> , 2003, 104, 16P-16P.	0.0	0
83	Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. <i>Clinical Science</i> , 2002, 103, 298S-301S.	4.3	3
84	ACE inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 337-337.	2.4	0
85	Peripheral Vascular Structure and Function in Men with Contrasting GH Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3309-3314.	3.6	9
86	Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 631-646.	2.4	271
87	Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH ₂ -terminal 20 peptide (PAMP). <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 159-164.	2.4	52
88	Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. <i>Hepatology</i> , 2001, 33, 826-831.	7.3	45
89	Gastrin-releasing peptide is a potent vasodilator in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 252-259.	4.7	18
90	Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. <i>British Journal of Pharmacology</i> , 2001, 134, 648-654.	5.4	74

#	ARTICLE	IF	CITATIONS
91	Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. <i>Journal of Physiology</i> , 2001, 530, 541-550.	2.9	151
92	Short-term effects of transdermal nicotine on acute tissue plasminogen activator release in vivo in man. <i>Cardiovascular Research</i> , 2001, 52, 321-327.	3.8	22
93	Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 295-301.	0.7	10
94	Venous endothelin receptor function in patients with chronic heart failure. <i>Clinical Science</i> , 2000, 98, 65-70.	4.3	15
95	Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and capacitance vessels in vivo. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 27-30.	2.4	11
96	Research methods in human cardiovascular pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 395-395.	2.4	1
97	Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: Upregulation of smooth muscle ETB receptors that modulate contraction. <i>British Journal of Pharmacology</i> , 2000, 130, 1735-1744.	5.4	15
98	S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. <i>British Journal of Pharmacology</i> , 2000, 131, 1236-1244.	5.4	54
99	Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro : implications for anti-thrombotic therapy. <i>British Journal of Pharmacology</i> , 2000, 131, 1391-1398.	5.4	31
100	The influence of heart rate on augmentation index and central arterial pressure in humans. <i>Journal of Physiology</i> , 2000, 525, 263-270.	2.9	913
101	A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 75-81.	4.7	14
102	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 67-74.	4.7	1
103	Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty. <i>Circulation</i> , 2000, 102, 1937-1943.	1.6	27
104	Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 336-344.	2.4	36
105	Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 507-513.	2.4	22
106	Endothelin Receptor Antagonists. <i>Drugs in R and D</i> , 1999, 2, 1-12.	2.2	8
107	Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 545-550.	2.4	123
108	Clinical Experience With Endothelin Antagonists. <i>American Journal of Hypertension</i> , 1998, 11, 71S-79S.	2.0	25

#	ARTICLE	IF	CITATIONS
109	Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. <i>BMJ: British Medical Journal</i> , 1998, 316, 834-837.	2.3	92
110	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. <i>Circulation</i> , 1998, 97, 2323-2330.	1.6	158
111	The endothelin system:a novel therapeutic target in cardiovascular disease. <i>Expert Opinion on Emerging Drugs</i> , 1998, 3, 95-112.	1.1	6
112	Seasonal Variation in Glucocorticoid Activity in Healthy Men¹. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 4015-4019.	3.6	132
113	Endothelial Dysfunction and Hypertension. <i>Drugs</i> , 1997, 53, 30-41.	10.9	57
114	Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. <i>British Journal of Pharmacology</i> , 1997, 120, 1376-1382.	5.4	93
115	Intraâ€arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 493-499.	2.4	35
116	Endothelin: from molecule to man. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 9-20.	2.4	60
117	The Clinical Section of the British Pharmacological Society: prospects for the future. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 215-218.	2.4	0
118	Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 327-333.	4.7	3
119	An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1242-1248.	3.4	80
120	The increase in human plasma immunoreactive endothelin but not big endothelinâ€1 or its Câ€terminal fragment induced by systemic administration of the endothelin antagonist TAKâ€044. <i>British Journal of Pharmacology</i> , 1996, 119, 311-314.	5.4	62
121	The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine. <i>Drugs</i> , 1996, 51, 12-27.	10.9	70
122	The endothelin system and its potential as a therapeutic target in cardiovascular disease. , 1996, 72, 109-148.		151
123	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. <i>Circulation</i> , 1996, 93, 1860-1870.	1.6	257
124	Endothelial Nitric Oxide Production and Insulin Sensitivity. <i>Circulation</i> , 1996, 93, 1331-1333.	1.6	254
125	Endothelin and blood pressure regulation. <i>Journal of Human Hypertension</i> , 1996, 10, 383-6.	2.2	0
126	The Role of Endothelin-1 in Cardiovascular Physiology and Pathophysiology. <i>Scottish Medical Journal</i> , 1995, 40, 69-71.	1.3	6

#	ARTICLE	IF	CITATIONS
127	Phosphoramidon inhibition of the <i>in vivo</i> conversion of big endothelin-1 to endothelin-1 in the human forearm. <i>British Journal of Pharmacology</i> , 1995, 116, 1821-1828.	5.4	47
128	Endothelin ET _A and ET _B Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. <i>Circulation</i> , 1995, 92, 357-363.	1.6	229
129	Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators. <i>Hypertension</i> , 1995, 25, 918-923.	2.7	304
130	Endogenous endothelin generation maintains vascular tone in humans. <i>Journal of Human Hypertension</i> , 1995, 9, 459-63.	2.2	14
131	Contribution of endogenous generation of endothelin-1 to basal vascular tone. <i>Lancet, The</i> , 1994, 344, 852-854.	13.7	577
132	Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 293-301.	2.4	3
133	Endothelins come of age. <i>Lancet, The</i> , 1993, 342, 1439-1440.	13.7	20
134	Endothelium-Dependent Modulation of Responses to Endothelin-1 in Human Veins. <i>Clinical Science</i> , 1993, 84, 427-433.	4.3	59
135	The Endothelin Family of Peptides: Local Hormones with Diverse Roles in Health and Disease?. <i>Clinical Science</i> , 1993, 84, 485-500.	4.3	213